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A B S T R A C T
Background: Depression, anxiety, and cognitive impairments occur in up to 40 % of adults with AF and are
associated with poorer health-related quality of life (HRQoL) and higher symptom burden. However, it is un-
known how often these impairments co-occur, or multimorbidity, and how multimorbidity effects HRQoL and
symptom burden.
Methods: Patients with AF age ≥65 years with a CHA2DS2VASC risk score ≥ 2 and eligible for oral antic-
oagulation therapy were recruited from five clinics in a prospective cohort study. Participants completed vali-
dated measures of depression (PHQ9) and anxiety (GAD7), cognitive impairment (MoCA), and HRQOL and AF
symptom burden (AFEQT). Multinomial logistic regression was used.
Results: Participants (N = 1244, 49 % female) were on average 76± 7 years; 86 % were non-Hispanic white.
Approximately 35 % of participants had 1 impairment, 17 % had 2 impairments and 8% had 3 impairments; 39
% had none of the 3 impairments examined. Compared to participants with no impairments, patients with 1, 2
and 3 impairments had higher odds of poor HRQoL (adjusted OR [AOR] = 1.77, 95 % CI 1.21, 2.60; AOR =
6.64, 95 % CI 4.43, 9.96; and AOR = 7.50, 95 % CI 4.40, 12.77, respectively) and those with 2 and 3 im-
pairments had higher odds of high symptom burden (AOR = 3.69 95 % CI 2.22, 6.13; and AOR = 5.41 95 % CI
2.85, 10.26).
Conclusions: Psychosocial/cognitive multimorbidity is common among older adults with AF and is associated
with poor HRQoL and high symptom burden. Clinicians might consider incorporating psychosocial and cognitive
screens into routine care as this may identify a high-risk population.
1. Introduction
With an estimated prevalence of 3–5 million adults, atrial fibrilla-
tion (AF) represents the most common cardiac rhythm abnormality.
(Wändell et al., 2016) Considering an aging population in the US and
that AF primarily affects older adults, prevalence of AF is expected to
more than double to 12 million by 2050. (Go, Hylek, & Phillips, 2001;
Wändell et al., 2016) Further, AF represents a significant economic
burden with health-related costs about $8700 higher per year than
those living without AF. (Roger, Go, & Lloyd-Jones, 2011) Treatment of
AF by attempting restoration of sinus rhythm with cardioversions, anti-
arrhythmic medications and catheter ablation has been shown to re-
duce symptoms and improve quality of life, but has no incremental
benefits on stroke, bleeding or mortality. (Packer, Mark, & Robb, 2019)
Further, guidelines suggest the use of health-related quality of life
(HRQoL) as a marker for treatment success in clinical practice and
HRQoL is increasingly included in clinical trials as an important patient
reported outcome of treatment. (Packer et al., 2019; McNamara, Brass,
& Drozda, 2004; Baron, Arnold, & Wang, 2017; Feldman, Mauri, &
Kahwash, 2018; Tan, Koh KWL, Lim, & Wang, 2018 Additionally,
symptom burden, an important driver of HRQoL, (Tan et al., 2018;
Randolph, Simon, & Thomas, 2016; Ha, Breithardt, & Camm, 2014 has
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been associated with poor outcomes including heart failure hospitali-
zation, stroke and mortality (Vermond, Crijns, & Tijssen, 2014); and
also influences anticoagulation prescription. (Steinberg, Kim, &
Thomas, 2014) Therefore, the assessment of HRQoL and symptom
burden and their association with other patient specific factors is an
important consideration.
Among patients with AF, it is estimated that 2 million patients also
live with a psychosocial (i.e., depression or anxiety) or cognitive im-
pairment. (Akintade, Chapa, Friedmann, & Thomas, 2015; Thrall, Lip,
Carroll, & Lane, 2007; Frasure-Smith, Lespérance, & Habra, 2009 Pa-
tients with psychosocial or cognitive impairments have poorer out-
comes including a greater risk for cardiovascular events, increased
healthcare utilization, increased symptom severity, poorer medication
adherence, increased all-cause mortality (Frasure-Smith et al., 2009;
Wändell et al., 2016; Flaker, Pogue, & Yusuf, 2010; Thrall, Lip, Carroll,
& Lane, 2007; Gehi, Sears, & Goli, 2012 and poorer HRQoL. (Charitakis,
Barmano, Walfridsson, & Walfridsson, 2017; Tan et al., 2018; Ong,
Cribbie, & Harris, 2006; Akintade, Chapa, Friedmann, & Thomas, 2015
Although there is evidence that individual psychosocial and cognitive
impairments may affect HRQoL and symptom burden in AF, little re-
search has examined whether increased impairment (i.e., multi-
morbidity) is associated with poorer clinical outcomes. Multimorbidity,
defined by WHO as “the existence of two or more chronic conditions in
the same individual,” has most often focused on the co-occurrence of
physical medical conditions (i.e., chronic conditions, frailty) rather
than psychosocial and cognitive conditions. (Vetrano, Palmer, &
Marengoni, 2018; Mercer, Zhou, & Humphris, 2018; Violan, Foguet-
Boreu, & Flores-Mateo, 2014; Forman, Maurer, & Boyd, 2018 Research
suggests that physical multimorbidity is associated with poorer HRQoL
in various chronic diseases including pulmonary disease, heart disease
and diabetes. (Fortin et al., 2004) Given the prevalence of psychosocial
and cognitive impairment in AF patients and the impact of physical
multimorbidity on health outcomes, it is possible that psychosocial and
cognitive multimorbidity may also impact health outcomes in AF pa-
tients.
Limited research in diabetes has found that psychosocial and cog-
nitive multimorbidity is associated with lower adherence to self-care
practices like physical activity and blood glucose monitoring. (Smith,
Pedneault, & Schmitz, 2015) With regards to AF and psychosocial and
cognitive multimorbidity, the literature is very limited. One study
found significantly lower HRQoL with higher psychosocial and cogni-
tive multimorbidity in patients with AF. (Bostrom, Saczynski, & Hajduk,
2017) However, the sample consisted of only symptomatic AF patients
from one geographic location and did not evaluate the relationships
between symptom burden and impairment. Utilizing a broader sample
of AF patients and evaluating the association between multimorbidity
and symptom burden, an important marker of AF severity, would
provide a more complete view of the impact of psychosocial and cog-
nitive multimorbidity in patients with AF. Further, little is known re-
garding patterns of psychosocial and cognitive multimorbidity in AF
(for example, which conditions co-occur most frequently), nor re-
garding factors and patient characteristics associated with psychosocial
and cognitive multimorbidity in AF. (Bostrom et al., 2017)
Given the importance of HRQoL as an endpoint of AF treatment and
the potential impact impairment and multimorbidity may have on
HRQoL and symptom burden, it is important to understand the burden
of psychosocial and cognitive multimorbidity and the relationship be-
tween multimorbidity and important patient reported outcomes in AF.
The objective of this study was to examine patterns of psychosocial and
cognitive multimorbidity in older adults with AF, patient characteristics
related to psychosocial and cognitive multimorbidity, and the associa-
tion between multimorbidity and HRQoL and symptom burden.
2. Methods
2.1. Study sample
The Systematic Assessment of Geriatric Elements in Atrial
Fibrillation (SAGE-AF) study is an ongoing prospective study of ger-
iatric conditions (e.g., frailty, cognitive impairment) and their re-
lationship to oral anticoagulation treatment in AF. The SAGE-AF study
has been previously described. (Saczynski, Sanghai, & Kiefe, 2020) In
brief, from June 2015 to June 2018, 1244 participants enrolled in
SAGE-AF. Enrollment for SAGE-AF is complete and 2 year follow ups
are ongoing. All 1244 participants were included in the analyses of the
present study. Study participants were recruited from 5 ambulatory
care sites in Massachusetts and Georgia. All sites were heterogeneous in
provider type (e.g., geriatric and family medicine, cardiology, cardiac
electrophysiology) and patient demographics, serve rural, suburban,
and urban populations, include a range of socioeconomic status from
middle class to extremely poor, and include private, academic and
hospital-owned practices. Sites were selected for their heterogeneity to
enhance the generalizability of our findings. Inclusion criteria included:
1) a history of AF; 2) Aged 65 years or older; and 3) A CHA2DS2VASC
risk score ≥ 2; 4) taking or eligible for oral anticoagulation therapy
with no contraindication to oral anticoagulation therapy. Participants
were excluded if they had documentation of an absolute contra-
indication to anticoagulant therapy or an indication for anticoagulant
therapy other than AF. Additionally, participants were not eligible for
enrollment if they could not speak English, were pregnant, were in
prison, could not provide informed consent, were diagnosed with de-
mentia, had a planned invasive procedure with possible uncontrollable
bleeding, or were unwilling or unable to participate in one and two year
follow-up assessments. Study participants with mild-moderate cogni-
tive impairment were included in this study. Although cognitive im-
pairment may impact a participant’s ability to self-report some factors
such as medication adherence, or food diaries, previous research shows
that even with moderate cognitive impairment patients are able to
accurately report medical conditions and respond to questionnaires
about how they feel, including depression and anxiety. (Snow, Kunik, &
Molinari, 2005; McGivney, Mulvihill, & Taylor, 1994; Bradford, Brenes,
& Robinson, 2013 Participants provided written informed consent. The
University of Massachusetts Medical School and Mercer University In-
stitutional Review Boards approved all study protocols.
2.2. Data abstraction
Data were collected through comprehensive baseline geriatric as-
sessments, structured interviews and a review of medical records.
Assessments and interviews were conducted by trained study staff fol-
lowing participants’ routine clinical visits. Structured interviews were
administered by study staff trained by SAGE-AF principal investigators.
Medical record review protocol used “gold standard” medical records
and required that each abstractor satisfactorily complete 10 practice
cases before certification. Quality control checks were conducted via
audited interviews and medical records abstracted in duplicate for 5%
random samples. If error rates were high, staff were retrained, and
additional quality controls were put into place until error rates de-
clined. Geriatric assessments and structured interviews consisted of
validated instruments to assess depression, anxiety, cognitive impair-
ment, HRQoL and symptom burden. Information abstracted from the
medical record by trained staff included participants’ age, race/ethni-
city, sex, comorbidities, type of AF, medication use and laboratory
values used to calculate CHA2DS2VASC and HAS-BLED risk scores.
Other demographic variables collected through structured interviews
include marital status, education and living situation.
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2.3. Health-related quality of life and symptom burden
HRQoL and symptom burden were measured using the validated
Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire.
(Spertus, Dorian, & Bubien, 2010) The AFEQT consists of several sub-
scales including symptom severity, AF burden, global well-being and
impact on health care utilization. (Spertus et al., 2010) The AFEQT is a
reliable measure (Cronbach’s alpha>0.8 for overall scale and sub-
scales) and is scored on a 0–100 scale, with higher scores indicating
better HRQoL. (Spertus et al., 2010) As there is no standard score to
indicate low HRQoL, we defined low HRQoL as AFEQT scores in the
lowest quartile (scores≤69.8). Symptom burden was measured using 4
items assessing how bothered participants have been by palpitations,
irregular heartbeats, pauses in heart activity and lightheadedness/diz-
ziness over the past four weeks. Any participant who reported being
quite, very, or extremely bothered by any of the symptoms were cate-
gorized as having high symptom burden.
2.4. Psychosocial and cognitive multimorbidity
Depressive symptoms were assessed using the 9-item Patient Health
Questionnaire (PHQ-9). (Kroencke, Spitzer, & Williams, 2001; Spitzer,
Kroenke, Williams, & Group PHQPCS, 1999) Scores range from 0 to 27
with higher scores indicating increased severity and 5 was used as a
cutoff point indicating mild or more severe depressive symptomology.
(Kroencke et al., 2001) The PHQ-9 has high sensitivity (0.88) and
specificity (0.88) for major depression in CVD patients. (Gilbody,
Richards, Brealey, & CJJogim, 2007; Stafford, Berk, & HJJGhp, 2007)
Anxiety was assessed using the 7-item Generalized Anxiety Disorder-7
scale (GAD-7). (Spitzer, Kroenke, Williams, & Löwe, 2006) GAD-7
scores range from 0 to 27 with higher scores indicating increased se-
verity (Spitzer et al., 2006) and a cutoff point of 5 was used to indicate
mild or more severe symptoms of anxiety. The GAD-7 has demonstrated
high sensitivity (0.89) and specificity (0.82) in a general population of
adults. (Spitzer et al., 2006) Cognitive function was assessed using the
validated 30-item Montreal Cognitive Assessment Battery (MoCA).
Scores range from 0 to 30 with lower scores indicating increased cog-
nitive impairment. A cutoff of 23 was used to indicate cognitive im-
pairment. (Saczynski, Inouye, & Guess, 2015) Among cardiovascular
patients, the MoCA demonstrates high internal consistency (0.83) and
high sensitivity (0.90). (Nasreddine, Phillips, & Bédirian, 2005) To
examine multimorbidity, patients were classified as having no impair-
ments, 1 impairment, 2 impairments, or all 3 impairments, where 2 or 3
impairments represented any combination of depression, anxiety and
cognitive impairment. Participants were categorized based on reported
individual impairments and impairment combinations.
2.5. Statistical analyses
Patient characteristics according to burden of impairment (0, 1, 2,
or 3 impairments) were compared using analysis of variance and
Kruskal-Wallis tests for continuous variables and Mantel-Haenszel χ
(Go et al., 2001) tests for categorical variables. Regarding 1 or 2, all
impairments and all combinations of impairments were included in the
analyses. Further, 3 impairments represent the presence of depression,
anxiety and cognitive impairment. Characteristics included partici-
pants’ age, race/ethnicity, sex, marital status, education, living situa-
tion, comorbidities, type of AF, medication use, CHA2DS2VASC and
HAS-BLED risk scores. Characteristics that differed significantly by
burden of impairment were included in a multinomial logistic regres-
sion to assess which participant characteristics were independently
associated with multimorbidity, using no impairment as the common
reference group. Similarly, using characteristics that differed sig-
nificantly by burden of impairment, we used logistic regression to as-
sess the association between multimorbidity and impaired HRQoL and
high symptom burden. A priori statistical significance was set at
p<0.05 for all statistical analyses. For any participant with missing
data for depression, anxiety or cognitive impairment, multiple im-
putation analysis was performed to predict the missing values. All
analyses were performed using SAS version 9.4 (SAS Institute, Inc,
Cary, NC).
3. Results
The results presented here include all 1244 SAGE-AF participants
who have complete baseline psychosocial, cognitive, HRQoL and
symptom burden data. Participants were on average 75.5±7.1 years,
86 % were non-Hispanic White, and 49 % were female. Most partici-
pants were married (57 %) while less than half (43 %) had a college
degree. In addition to having AF, the majority of participants had a
diagnosis of hypertension (90 %) and hyperlipidemia (80 %). The
majority of patients (86 %) were prescribed an oral anticoagulant; 36 %
and 6% were prescribed aspirin and anti-platelets, respectively.
3.1. Psychosocial and cognitive impairment
The majority of participants (N = 755, 61 %) had at least one
psychosocial or cognitive impairment (Fig. 1). Cognitive impairment
occurred the most frequently among participants (42 %), followed by
elevated depressive symptoms (28 %) and elevated symptoms of an-
xiety (24 %). Thirty-five percent of participants had 1 impairment, 17
% had 2 impairments, and 8% had 3 impairments; 39 % had none of the
3 impairments. Regarding specific co-occurrence of impairments, de-
pression and anxiety more often co-occurred with another impairment
rather than alone (Fig. 1). Conversely, cognitive impairment more often
occurred alone.
Age, race/ethnicity, gender, education, marital status,
CHADS2VASC score, HAS-BLED score and the prevalence of heart
failure, coronary artery disease, hypertension, diabetes, renal failure,
stroke and implantable cardiac devices differed by number of psycho-
social and cognitive impairment (Table 1).
3.2. Factors associated with psychosocial and cognitive multimorbidity
After multivariate adjustment, several participant characteristics
were significantly associated with psychosocial and cognitive multi-
morbidity (Table 2). The characteristic with the strongest association
with multimorbidity was race/ethnicity where patients with races/
ethnicities other than non-Hispanic White had 4x, 3x and 8x the odds of
having 1 impairment (OR = 4.48, 95 % CI 2.69, 7.46), 2 impairments
(OR = 2.95, 95 % CI 1.64, 5.34) and 3 impairments (OR = 8.18, 95 %
CI 4.24, 15.79). Older participants and those with less formal education
had significantly higher odds of having 1 impairment (Age OR = 1.05,
95 % CI 1.03, 1.07; Some college or less OR = 1.51, 95 % CI 1.13, 2.00)
and 3 impairments (Age OR = 1.07, 95 % CI 1.03, 1.10; Some college
or less OR = 2.01, 95 % CI 1.19, 3.39). Patients with implantable
cardiac devices were more likely to have psychosocial and cognitive
impairments (1 impairment OR = 1.80, 95 % CI 1.31, 2.48; 2 im-
pairments OR = 1.84, 95 % CI 1.25, 2.70; 3 impairments OR = 2.78,
95 % CI 1.69, 4.57) than patients without implantable cardiac devices.
3.3. Psychosocial or cognitive multimorbidity and poor health-related
quality of life
We examined the association between psychosocial and cognitive
multimorbidity and poor HRQoL using logistic regression. The number
of psychosocial and cognitive impairments showed a dose-response
relationship with poor HRQoL after adjusting for age, race, sex, edu-
cation and medical comorbidities. About 1 in 8 (12 %) of patients with
no impairments had poor QOL compared to 20 % of patients with 1
impairment, 50 % of patients with 2 impairments, and 54 % of patients
with 3 impairments (Table 3). Compared to participants without
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psychosocial or cognitive impairments, those with 1 impairment had
1.8 times the odds of reporting poor HRQoL (Adjusted OR= 1.75, 95 %
CI 1.19, 2.56), those with 2 impairments were 6.6 times as likely to
report poor HRQoL (Adjusted OR= 6.60, 95 % CI 4.40, 9.89) and those
with 3 impairments were more than 7.5 times as likely to report poor
HRQoL (Adjusted OR = 7.59, 95 % CI 4.46, 12.91; Table 3). Associa-
tions between each individual impairment and low HRQoL are pre-
sented in supplemental Table 1. There was a significant relationship
between participants with impairments and low HRQoL. Specifically, a
greater proportion of participants with depression only; anxiety only;
depression and anxiety; depression and cognitive impairment; anxiety
and cognitive impairment; and depression, anxiety and cognitive im-
pairment had low HRQoL compared to those with no impairment.
3.4. Psychosocial or cognitive multimorbidity and high symptom burden
We also examined the association between psychosocial and cog-
nitive multimorbidity and high symptom burden using logistic regres-
sion (Table 4). There was a dose-response relationship between the
number of psychosocial and cognitive impairments and high symptom
burden after adjusting for age, race, sex, education and medical co-
morbidities. Less than a tenth (7%) of patients with no impairments had
high symptom burden compared to 8% of patients with 1 impairment,
21 % of patients with 2 impairments, and 24 % of patients with 3 im-
pairments (Table 4). Compared to participants without psychosocial or
cognitive impairments, those with 2 impairments were 3.7 times as
likely to report high symptom burden (Adjusted OR = 3.69 95 % CI
2.22, 6.13) and those with 3 impairments were more than 5.4 times as
likely to report high symptom burden (Adjusted OR = 5.41 95 % CI
2.85, 10.26; Table 4). Associations between each individual impairment
and high symptom burden are presented in supplemental Table 1. There
was a significant relationship between participants with impairments
and high symptom burden. Specifically, a greater proportion of parti-
cipants with depression only; depression and anxiety; depression and
cognitive impairment; and depression, anxiety and cognitive impair-
ment had high symptom burden compared to those with no impair-
ment.
4. Discussion
In our sample of 1244 older adults with AF, we found 60 % of pa-
tients had at least 1 psychosocial and cognitive impairment, and 25 %
were living with psychosocial and cognitive multimorbidity. Though
multimorbidity has received increased attention in the treatment of
chronic illness, few studies have explored psychosocial and cognitive
multimorbidity. In the present study, we found that multimorbidity was
more likely among participants who were racial/ethnic minorities,
older, less educated and those with medical comorbidities.
Additionally, few studies have evaluated psychosocial and cognitive
multimorbidity and its effect on HRQoL and symptom burden in AF. In
the present study we found that patients with greater psychosocial and
cognitive multimorbidity were substantially more likely to experience
poorer HRQoL and high symptom burden, two important patient-re-
ported outcomes in AF.
Overall rates of psychosocial and cognitive impairments reported in
this study are similar to those reported in previous studies evaluating
the prevalence of psychosocial and cognitive impairment in AF samples.
(Akintade et al., 2015a; Thrall et al., 2007a; Frasure-Smith et al., 2009,
(Bostrom et al., 2017) The current study extends the literature by
showing that among those with any impairment, 41 % had at least one
additional psychosocial or cognitive impairment. Once a provider
identifies or suspects a patient has an impairment, it may be prudent to
Fig. 1. Multimorbid Psychosocial and Cognitive Impairments among Older Adults with Atrial Fibrillation, The SAGE-AF Study (N = 1244).
B.A. Bamgbade, et al. Archives of Gerontology and Geriatrics 90 (2020) 104117
4
screen for other potential psychosocial or cognitive impairments,
especially in the case of depression or anxiety, which most often co-
occurred in our cohort.
Previous research in symptomatic AF adults with psychosocial and
cognitive impairment found associations between impairment and
older age and less formal education. (Bostrom et al., 2017) We found
race/ethnicity was the characteristic most strongly associated with
cognitive and psychosocial multimorbidity among older adults with AF.
Reports are mixed regarding whether individual psychosocial and
cognitive impairments occur more frequently in non-Hispanic White
patients or patients of other races/ethnicities. (Sheffield & Peek, 2011;
Lee et al., 2012; Steffens, Fisher, Langa, Potter, & Plassman, 2009;
Williams, Gonzalez, & Neighbors, 2007; Weinberger et al., 2018;
Asnaani, Richey, Dimaite, Hinton, & Hofmann, 2010; Williams,
Gonzalez, & Neighbors, 2007; Kessler, Chiu, Demler, & Walters, 2005;
Himle, Baser, Taylor, Campbell, & Jackson, 2009 There is evidence that
rates of cognitive impairment are higher in racial/ethnic minorities
(Lee et al., 2012; Sheffield & Peek, 2011) while depression (Steffens
et al., 2009; Weinberger et al., 2018; Williams et al., 2007b) and an-
xiety (Asnaani et al., 2010; Himle et al., 2009; Kessler et al., 2005) are
more common among non-Hispanic White adult and older adult pa-
tients. However, our results suggest that regardless of actual prevalence
of individual impairments, the burden of psychosocial and cognitive
multimorbidity disproportionately effects racial/ethnic minority older
patients with AF. Though unexplored in previous research, this
increased burden may contribute to disparities that exist across race
and ethnicity in AF. (Ugowe, Jackson, & Thomas, 2018; Goli,
Thompson, & Sears, 2012; Golwala, Jackson, & Simon, 2016 For in-
stance, there is strong evidence that in AF, racial/ethnic minorities have
a 24–60 % higher risk of stroke, 2–4 times higher risk of intracranial
hemorrhage and 46 % higher risk of death. (Ugowe et al., 2018) Ad-
ditionally, racial/ethnic minorities report significantly more impaired
functional status and poorer quality of life. (Goli et al., 2012; Golwala
et al., 2016) It is possible that psychosocial and cognitive impairment in
racial/ethnic minority patients may contribute to these disparities in
racial/ethnic minority older patients with AF and that screening for
cognitive impairment, depression and anxiety could identify a high-risk
subgroup.
Findings from this study build on evidence regarding the im-
portance of anxiety, depression and cognitive impairment in AF and
extend the literature by highlighting the influence of psychosocial and
cognitive multimorbidity, which has otherwise been neglected. With 1
impairment, patients were twice as likely to report poor HRQoL than
those with no impairments, and this increased substantially to 7–8
times more likely in patients with 2 or 3 impairments. This suggests that
the effects of multimorbidity on HRQoL may be multiplicative rather
than additive, further highlighting the need to screen for these im-
pairments. Additionally, we found that psychosocial and cognitive
multimorbidity was associated with high symptom burden. This finding
aligns with literature showing associations between individual
Table 1
Cohort Characteristics by Burden of Psychosocial or Cognitive Impairment (Elevated Depressive Symptoms, Elevated Anxiety Symptoms, and/or Cognitive
Impairment) among Older Adults with AF: The SAGE-AF Study (N = 1244).
Characteristic No Impairments
(N = 489)
1
Impairment
(N = 441)
2 Impairments
(N = 210)
3
Impairments
(N = 104)
Age (mean, std) 74.2 (6) 76.9 (7) 74.9 (8) 77.6 (8)
Race/ethnicity other than non-Hispanic White 24 (5) 82 (19) 34 (16) 35 (34)
Female 221 (45) 211 (48) 114 (54) 61 (59)
Married or Living as married 296 (61) 242 (56) 106 (52) 50 (50)
Educationa
Some college or less
College graduate or more
229 (47)
257 (53)
269 (62)
163 (38)
121 (60)
82 (40)
74 (75)
25 (25)
Living Situationb
Alone
With spouse or others
138 (28)
348 (72)
120 (28)
315 (72)
59 (29)
144 (71)
33 (33)
68 (67)
Medical History
Heart failure
Coronary artery disease
Peripheral vascular disease
Hypertension
Diabetes
Hyperlipidemia
Stroke
Renal failure
Implantable cardiac device
134 (27)
39 (8)61 (13)
425 (87)
116 (24)384 (79)
38 (8)
115 (24)
105 (21)
187 (42)
57 (13)67 (15)
402 (91)
122 (28)355 (81)
46 (10)
130 (29)
177 (40)
84 (40)
20 (10)33 (16)
195 (93)
73 (35)175 (83)
21 (10)
68 (32)
80 (38)
58 (56)
17 (16)18 (17)
100 (96)
35 (34)82 (79)
17 (16)
43 (41)
59 (57)
Clinical Characteristics
AF Type- Paroxysmal
CHADS2VASC score (median, IQR)
HASBLED score (median, IQR)
282 (58)
4.0 (2.0)
3.0 (2.0)
256 (58)4.0 (3.0)
3.0 (1.0)
143 (68)5.0 (3.0)
3.0 (1.0)
60 (58)5.0 (2.0)
3.0 (1.0)
Treatment Characteristics
Anticoagulant use
Aspirin use
Other anti-platelet use
Depression: PHQ-9 (mean, std)
Anxiety: GAD-7 (mean, std)
Cognitive Impairment: MoCA (mean, std)
Health-related Quality of Life: AFEQT (mean, std)
423 (87)
162 (33)
24 (5)
1.3 (1.3)
0.9 (1.2)
26.3 (1.7)
85.6 (13.9)
372 (84)
166 (38)
28 (6)
2.6 (3.0)
1.7 (2.3)
21.8 (4.1)
82.3 (16.1)
174 (83)
78 (37)
17 (8)
7.3 (4.0)
5.8 (3.9)
22.8 (4.5)
69.3 (19.9)
95 (91)
36 (35)
10 (10)
10.0 (4.2)
9.2 (3.7)
19.7 (3.4)
65.6 (20.8)
Continuous variables are presented as mean± standard deviation or median and IQR and categorical variables are presented as n (%).
Impairments = depression, anxiety or cognitive impairment; AF = Atrial Fibrillation, PHQ-9= Patient Health Questionnaire, GAD-7= Generalized Anxiety Disorder
7 Scale, MoCA = Montreal Cognitive Assessment Battery, AFEQT = Atrial Fibrillation Effect on QualiTy-of-life.
Bold indicates statistical significance p< 0.05.
a Some college or less = high school or less; some college. College graduate or more = college graduate; graduate degree.
b With spouse or others = with spouse; with family other than spouse; with people other than family; nursing home.
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impairments (e.g., depression only, anxiety only) and higher symptom
burden (Walters, Wick, & Tan, 2019; Kang, 2006; Katon, Lin, &
Kroenke, 2007; Thompson et al., 2014 and extends existing literature
by showing associations between cognitive impairment only and higher
symptom burden. Regarding associations of each impairment with
HRQoL (supplemental Table 1), except for cognitive impairment only, a
greater proportion of participants with all individual impairments and
impairment combinations had low HRQoL compared to those with no
impairment. These findings align with previous research evaluating
individual impairments and also aligns with our interest in exploring
the impact of psychosocial and cognitive multimorbidity on HRQoL.
(Bostrom et al., 2017; Charitakis et al., 2017; Thrall et al., 2007a) Re-
garding associations of each impairment with symptom burden (sup-
plemental Table 1), a greater proportion of participants with depression
only or depression with any other impairment had high symptom
burden compared to those with no impairment. To our knowledge,
there are no studies evaluating the impact of cognitive impairment on
symptom burden. There is limited evidence showing an association
between symptom burden and anxiety (Charitakis et al., 2017;
Thompson et al., 2014; Walters et al., 2019). Our findings suggest that
depression may play a larger and unexplored role in the relationship
between other impairments and symptom burden. More research is
needed to further explore contributions of each impairment to symptom
burden when there are 2 or more psychosocial a cognitive impairment.
Poor HRQoL and high symptom burden are linked to increased
emergency department visits and hospitalizations in AF, (Freeman,
Simon, & Go, 2015; Streur, Ratcliffe, Callans, Shoemaker, & Riegel,
2018) and it is possible that psychosocial and cognitive multimorbidity
identifies a population at higher risk for increased health care utiliza-
tion who may benefit from tailored interventions or who may have an
optimal risk-benefit profile for treatment options aimed at restoration
of sinus rhythm. Further, using psychosocial and cognitive multi-
morbidity as an indicator for poor HRQoL may be useful in clinical
practice as there is evidence of discordance between provider and pa-
tient HRQoL ratings in AF patients and that this discordance is medi-
ated by depression. (von Eisenhart Rothe et al., 2013) More research in
cognitive and psychosocial multimorbidity is needed to further explore
how multimorbidity relates to other important clinical outcomes such
as medication adherence, bleeding outcomes and mortality. Given that
the prevalence of psychosocial and cognitive multimorbidity and its
impact on HRQoL and potential impact on health outcomes, clinicians
might consider incorporating psychosocial and cognitive screens into
routine patient care.
4.1. Strengths and limitations
The present study has several strengths. Our study population is
comprised of geographically diverse older adults with a high degree of
comorbidity consistent with contemporary “real world” AF patients.
Further, our study included a comprehensive assessment of clinical and
patient reported factors utilizing validated and publicly available in-
struments. Our study is not without limitations. Though results from
Table 2
Adjusted Odds Ratios (95 % Confidence Intervals) for Burden of Psychosocial or
Cognitive Impairment in Relation to Cohort Characteristics: The SAGE-AF Study
(N = 1244).
1
Impairment
(N = 441)
2 Impairments
(N = 210)
3
Impairments
(N = 104)
Age 1.05
(1.03, 1.07)
1.01
(0.98, 1.03)
1.07
(1.03, 1.10)
Non-White Race 4.48
(2.69 7.46)
2.95
(1.64, 5.34)
8.18
(4.24, 15.79)
Female 1.04
(0.78, 1.37)
1.44
(1.02, 2.03)
1.62
(1.00, 2.61)
Educationa
Some college or less
1.51
(1.13, 2.00)
1.30
(0.92, 1.85)
2.01
(1.19, 3.39)
Medical History
Heart failure 1.33
(0.97, 1.82)
1.14
(0.78, 1.68)
1.64
(0.99, 2.71)
Coronary artery disease 1.61
(1.02, 2.54)
1.06
(0.58, 1.93)
1.97
(0.99, 3.94)
Hypertension 1.12
(0.72, 1.77)
1.49
(0.81, 2.74)
1.95
(0.67, 5.70)
Diabetes 0.99
(0.71, 1.38)
1.33
(0.90, 1.97)
0.98
(0.57, 1.68)
Renal failure 0.88
(0.63, 1.23)
1.08
(0.72, 1.61)
1.02
(0.61, 1.72)
Implantable cardiac device 1.80
(1.31, 2.48)
1.84
(1.26, 2.70)
2.78
(1.69, 4.57)
Stroke 1.15
(0.71,1.87)
1.04
(0.57,1.92)
1.46
(0.73,2.940)
No impairment is referent group. Impairments = depression, anxiety or cog-
nitive impairment; AF = Atrial Fibrillation.
Bold indicates statistical significance p<0.05.
a Some college or less = high school or less; some college. College graduate
or more = college graduate; graduate degree.
Table 3
Unadjusted and Adjusted Odds Ratios (95 % Confidence Intervals) for Low
Atrial Fibrillation Effect on Quality of Life (AFEQT) in Relation to Cohort
Characteristics and Burden of Psychosocial or Cognitive Impairment: The SAGE-
AF Study (N = 1244)a.
Low Health-Related Quality of Lifea
Low
HRQOL
N (%)
Unadjusted OR
(95 % CI)
Adjusted OR
(95 % CI)
Number of Impairments
0 impairments 60 (12) (Reference) (Reference)
1 Impairment 86 (20) 1.73
(1.21, 2.48)
1.75
(1.19, 2.56)
2 Impairments 105 (50) 7.15
(4.88, 10.48)
6.60
(4.40, 9.89)
3 Impairments 56 (54) 8.34
(5.21, 13.36)
7.59
(4.46, 12.91)
Demographic Covariates
Age 0.95
(0.93, 0.97)
Female 2.16
(1.61, 2.92)
Race/ethnicity other than non-
Hispanic White
1.00
(0.65, 1.52)
Educationb
Some college or less
College graduate or more
0.84
(0.61, 1.14)
Clinical Covariates
Heart failure 1.54
(1.11, 2.13)
Coronary artery disease 1.20
(0.75, 1.91)
Hypertension 1.12
(0.66, 1.89)
Diabetes 1.21
(0.87, 1.69)
Renal failure 0.99
(0.70, 1.39)
Implantable cardiac devices 1.25
(0.91, 1.72)
Stroke 0.74
(0.45, 1.24)
High AFEQT is referent group. Impairment = depression, anxiety or cognitive
impairment; AF = Atrial Fibrillation; AFEQT = Atrial Fibrillation Effect on
Quality of Life.
Bold indicates statistical significance p< 0.05.
a Based on AFEQT: Low AFEQT = score ≤69.8; High AFEQT = score>
69.8.
b Some college or less = high school or less; some college. College graduate
or more = college graduate; graduate degree.
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this study showed race/ethnicity was an important predictor in im-
pairment, 86 % of the SAGE-AF cohort is non-Hispanic White and
therefore we were unable to explore differences in impairment in spe-
cific racial/ethnic groups (e.g., Black/African-American, Hispanic/
Latinx) due to small cell sizes. Additionally, due to the cross-sectional
nature of our analysis, we are unable to assess the temporality of ob-
served associations, for example whether psychosocial and cognitive
impairments precede declines in HRQOL and increased AF symptom
burden, or whether worsening physical health leads to the development
of psychosocial and cognitive impairments. Longitudinal research is
needed to further explore these relationships. Lastly, there may be other
unmeasured confounding factors that affect associations between psy-
chosocial and cognitive multimorbidity and HRQoL and symptom
burden including social determinants of health like neighborhood and
physical environment or access to health care.
5. Conclusions
Psychosocial and cognitive multimorbidity is common among older
adults with AF and older, less educated, racial/ethnic minority adults
with medical comorbidities are more likely to have psychosocial and
cognitive multimorbidity. Psychosocial and cognitive multimorbidity
was associated with poor HRQoL and high symptom burden when
compared to individual psychosocial and cognitive impairments. Given
evidence that poor HRQoL and high symptom burden are associated
with poorer outcomes, our findings suggest that incorporating psy-
chosocial and cognitive screens into routine patient care may be ne-
cessary to identify a vulnerable group of patients who may benefit from
closer follow-up and tailored interventions.
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